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Recent peritonitis associates with mortality among patients treated with
peritoneal dialysis
Abstract
Peritonitis is a major complication of peritoneal dialysis, but the relationship between peritonitis and
mortality among these patients is not well understood. In this case-crossover study, we included the 1316
patients who received peritoneal dialysis in Australia and New Zealand from May 2004 through December
2009 and either died on peritoneal dialysis or within 30 days of transfer to hemodialysis. Each patient
served as his or her own control. The mean age was 70 years, and the mean time receiving peritoneal
dialysis was 3 years. In total, there were 1446 reported episodes of peritonitis with 27% of patients having
≥2 episodes. Compared with the rest of the year, there were significantly increased odds of peritonitis
during the 120 days before death, although themagnitude of this association wasmuch greater during the
30 days before death. Compared with a 30-day window 6 months before death, the odds for peritonitis
was six-fold higher during the 30 days immediately before death (odds ratio, 6.2; 95% confidence interval,
4.4–8.7). In conclusion, peritonitis significantly associates with mortality in peritoneal dialysis patients.
The increased odds extend up to 120 days after an episode of peritonitis but themagnitude is greater
during the initial 30 days.
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Abstr act:
Patients on peritoneal dialysis have a high annual mortality rate. Peritonitis is also a major
complication of peritoneal dialysis but the association between peritonitis and mortality has
not been examined systematically. Our aim was to determine the relationship between
peritonitis and mortality in patients on peritoneal dialysis. This was a case-crossover study
where individual patients served as their own control. All people receiving peritoneal dialysis
in Australia and New Zealand between 1st May 2004 and 31st December 2009 and died on
peritoneal dialysis, or within 30 days of transfer to hemodialysis, were included. 1316
patients were included with a mean age of 70.4±11.7 years and receiving peritoneal dialysis
for 2.9±2.0 years. 1446 episodes of peritonitis were reported with 27% of patients having 2 or
more episodes. A significantly increased odds of peritonitis prior to death compared with the
rest of the year was seen up to 120 days before death, although the magnitude of this
association was much greater in the immediate 30 days before death. The odds ratio of
peritonitis in the 30 days prior to death compared to a 30 day window 6 months prior to death
was 6.2 (95% confidence interval 4.4, 8.7). In conclusion, peritonitis was significantly
associated with mortality in peritoneal dialysis patients. This increased odds extended up to
120 days following an episode of peritonitis but the magnitude is greater in the initial 30 days
and it may be that the latter is the preferred new definition of peritonitis-associated mortality.
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Intr oduction:
Annual mortality for peritoneal dialysis (PD) patients is between 10 and 20%. 1 Infectious
causes of death account for a variable proportion of deaths on PD, 5.9 to 33%, depending
upon the publication examined and the population studied.1-3 The majority of these infections
in PD patients are due to peritonitis, with rates varying between centres. It is difficult though
to ascertain the definition of infection-, in particular peritonitis-, associated death as often it is
a clinical diagnosis without any clearly defined criteria.

The evidence that peritonitis increases a patient’s risk of death is primarily descriptive in
nature or extrapolated from peritonitis outcomes in non-dialysis patients.4-5 There has been
limited statistical analysis formally examining the relationship between peritonitis and death,
primarily related to the brevity and intermittent nature of the at-risk period.6 The patient that
has peritonitis and is septic then dies, clearly has a likely causal relationship between the two.
However, the inflammatory state that an infection creates within an individual may also
predispose to vascular events, especially in those with pre-existing disease, possibly leading
to cardiovascular or cerebrovascular death.7-9 These events may even occur a period of time
after an infection.10

Our aim was to explore the relationship between mortality and peritonitis in PD patients by
determining whether peritonitis was more likely to occur in the time immediately before
death than in periods distant to death. We utilise a case-crossover design to compare the
likelihood of peritonitis at different times, where individual patients serve as their own
control.11
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Results:
There were 1316 PD patients who died while receiving PD treatment (or within 30 days of
transfer to hemodialysis) included in the analyses, 44% of whom were female. Patients mean
age at death was 70.4±11.7 years, with a mean time on PD of 2.9±2.0 years (Table 1).
Patients were predominantly Caucasian (78%), with 10.7% Asians and 8.9% Aboriginal or
Torres Strait Islanders (ATSI). A total of 1446 peritonitis episodes were documented, with
56% experiencing ≥1 episode, and 27% ≥2. Mortality was attributed to peritonitis in 6% of
deaths. The median (25th and 75th percentile) time between peritonitis episode and death
was 247 days (64-552) (Figure 1).

Of the 250 patients with an episode of peritonitis in the 30 days prior to death, 69 (27.6%)
had peritonitis as the stated cause of death. For the remaining patients the cause of death was
categorised as cardiac (68, 27.2%), withdrawal (40, 16%), non-peritoneal infection (20, 8%),
cerebrovascular (13, 5.2%), malignancy (7, 2.8%), peripheral vascular events (5, 2%), and
other causes (28, 11.2% including bowel infarction, gastrointestinal haemorrhage, cachexia
and abdominal perforation).

Determination of the duration of the ‘window’ period
In order to ascertain the preferred duration of the window to be used in this analysis, 5- and
7- day windows were used at intervals prior to death and the occurrence of peritonitis during
that window was compared to all of the preceding periods up to 12 months before death
(Figure 2a and 2b). The odds of peritonitis in any 5 day period more than 30 days prior to
death were no different than any other early period in the year before death (Figure 2a).
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However, patients were more than 2.5-times more likely to have peritonitis in the window 30
days before death (95% confidence interval (CI)=1.7-3.6, P<0.001) than during any earlier
period and the odds ratio increased to 4.1 times in the 5-days immediately before death
(95%CI=3.2-5.3 p<0.001). A similar pattern was observed using 7-day windows, with the
risk of peritonitis significantly increased from 28 days to 7 days immediately before death
(odds ratio (OR) range 2.9-5.7). Since there were statistically significant odds ratios for both
5 and 7 day windows until 30 days prior to death, 30 days was utilised as the duration of the
windows to examine the association between mortality and peritonitis.

Potential at risk period of the association between peritonitis and mortality
Upon utilising a 30 day window at different intervals before death and comparing the
incidence of peritonitis with all other 30 day windows in the 12 months prior to death, there
was a significantly increased odds of peritonitis up to 120 days prior to death but the
magnitude of this association was much greater in the first 30 days (OR=6.5, 95%CI=5.4-7.7,
P<0.001) (Figure 2c).

Magnitude of the odds of peritonitis prior to death
In the 30 days immediately prior to death, 250 (19.0%) patients experienced an episode of
peritonitis, compared to 88 (6.7%) in the 30 days 6 months before death. The OR of
peritonitis in the 30 days prior to death compared to a 30 day window 6 months prior to death
was statistically significant at 6.2 (95%CI = 4.4, 8.7) (Table 2). Similar statistically
significant associations were seen when the comparator period was 3 and 9 months prior to
death.
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Association of peritonitis and cause of death specific mortality
A significantly increased odds of peritonitis in the 30 days prior to death was detected in
patients who died from cardiovascular, cerebrovascular or peripheral vascular disease
(OR=3.4, 95%CI=2.4, 4.6) (Figure 3a). Similar findings were detected in patients who died
from infectious causes and those that were coded as having withdrawn from dialysis (Figure
3b and c).

Sensitivity analysis
Sensitivity analysis of the 30 day window demonstrated that there was no significant
difference in the odds ratio of peritonitis at varying time periods prior to death more remote
than the period immediately prior to death (Table 3). This was consistent when only PD
patients with one episode of peritonitis were included.

Demographic and clinical predictors of peritonitis in the 30 days prior to death
Peritonitis in the 30 days prior to death was significantly associated with history of coronary
artery disease, time spent on peritoneal dialysis and the number of peritonitis episodes they
had previously. The odds ratio of peritonitis in the 30 days before death increased by 1.07 for
each additional year spent on PD (95%CI=1.00-1.15, P=0.049), and by 1.70 for each
additional case of peritonitis (95%CI=1.55-1.89, P<0.001). However, patients with a history
of coronary artery disease were less likely to have peritonitis in the 30 days prior to death
compared with those without this comorbidity (OR=0.71, (95%CI=0.51-0.99, P=0.048).
(Table 4).
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Discussion:
Patients on PD have an annual mortality rate of 10-20%.1 In Australia and New Zealand, 15%
of PD patients that died were coded as having done so due to infections, with approximately
6% due to peritonitis.1 In fact, 19% of PD patients died with peritonitis occurring in the
preceding 30 days. We have demonstrated that in those patients that died on PD there was an
approximately 6-fold increase in the odds of peritonitis in the 30 days before death compared
to the 30-day period 6 months prior to death.

There is currently no standard definition of peritonitis-associated mortality. Not surprisingly
therefore, there is appreciable variation in the reported prevalence of peritonitis-associated
mortality in the literature, ranging from 5.9% up to 33% of deaths.2-3, 12 Although a
proportion of this variability reflects differences in case-mix and racial origins, coding
differences are also likely to contribute.

In many cases, the diagnosis of peritonitis-associated death is made by the treating physician
and is somewhat subjective. Some physicians may only diagnose peritonitis-associated
mortality in cases where the patient presented with systemic manifestations of sepsis and
immediately died, while others include all deaths following a period of time after an episode
of peritonitis. For example, a previous series of publications from the ANZDATA Registry
defined peritonitis-associated mortality as “death directly attributable to peritonitis in the
clinical opinion of the treating nephrologist”.13-21 In contrast, Perez-Fontan et al defined
peritonitis-associated mortality as death “a) during the course of a clinically active peritonitis,
or b) during the week following complete clinical, bacteriologic, and cytological remission of
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an episode of peritonitis, or c) in the case of a refractory peritonitis demanding catheter
removal, before hospital discharge for reinitiation of regular dialysis therapy (PD or HD)”.22
Alternatively, Szeto et al defined peritonitis-associated mortality as “death from any cause
during antibiotic treatment (generally 2 to 3 weeks, depending upon the organism) or death
during temporary hemodialysis (generally four weeks after catheter removal)”.23

It is difficult to define the length of the at-risk period following peritonitis. It may be that the
risk of mortality is elevated only during the couple of weeks of active inflammation or it may
extend past this point. These variable and subjective approaches to diagnosing peritonitisassociated death make it exceedingly difficult to compare, contrast and explore observed
differences in peritonitis-associated death rates between different centres, regions and
countries. Our results would make a case for diagnosing peritonitis-associated death as any
death within 30 days of an episode of peritonitis. Our finding of significantly greater odds of
peritonitis in the period just prior to death was consistent using different periods of time
distant from death. The sensitivity analysis confirmed that this finding was not related to
increased peritonitis risk with time on dialysis.

Most studies that have examined factors that may influence patient survival in PD
populations have failed to include peritonitis as an independent variable.2, 24-25 Sipahioglu et
al, in their single centre retrospective study of 423 PD patients, demonstrated that for every
increase in peritonitis rate by one episode per 12 patient months there was an associated 1.87
fold increased relative risk of mortality.6 This was performed by entering the peritonitis rates
into a Cox proportional hazards model which may not be appropriate as these models are not
well suited to intermittent exposures with time-varying effects.26 This approach would also
9

have difficulties in selecting an appropriate control group (i.e. patients who did not die on
PD). These patients are likely to be fundamentally different from those who die on PD and
this approach may introduce control-selection biases.

We chose to use a case-crossover design. This method is used to determine the relationship
between an intermittent exposure and an outcome.27-28 A case-crossover study differs from a
case-control study in that all participants are cases (i.e. all have experienced the outcome), all
have had the opportunity to be exposed and unexposed at different study periods, because the
risk posed by the exposure is transient. Rather than having case and control patients, the casecrossover design uses case and control periods of time to determine whether the exposure
occurs more often in the ‘case’ period, immediately before the event, than in the ‘control’
period/s, more distant to the outcome.27 Therefore, the case-crossover design assesses the
timing of the exposure relative to the outcome, using participants as their own controls.

The advantage of this design is that it examines the association between time-varying
exposures on an outcome while controlling for constant patient-level confounders and
avoiding control-selection bias.29 The main limitations of case-crossover studies are that they
do not account for within-person (time-varying) confounders, or account for the role of
chronic exposures.27 The design we used ensured that stable patient factors such as age,
ethnicity and baseline co-morbidity were controlled for, however the design did not account
for patient factors which may have changed rapidly, such as nutritional status, anaemia, or
volume status.

We selected this design given that PD patients may be repeatedly exposed and unexposed to
peritonitis during their treatment, and that the risk of mortality posed by peritonitis is
10

unknown but it would be reasonable to assume that if an increased risk exists it is likely to be
time-limited. The case-crossover design allowed us to determine whether peritonitis was
more likely to occur in the period immediately before death for PD patients than during
earlier periods. A recent paper used this methodology to identify eight potential trigger
factors immediately prior to the rupture of intracranial aneurysms in 250 patients.30 Similarly,
mobile phones were demonstrated to be associated with motor vehicle accidents using this
technique .31

The finding in the present investigation of an increased risk of death for up to 120 days
following an episode of peritonitis may be potentially explained by a persistent systemic
inflammatory state, which may predispose them to cardiovascular events.7-9, 32 This
inflammatory state may lead to cardiovascular or cerebrovascular events that are remote to
the time of the peritonitis.7-9 Our finding that there is a significant association between
peritonitis and death from vascular disease is supportive of this hypothesis. There are other
possible mechanisms explaining why peritonitis may be associated with increased mortality,
including through its effects on increased frailty, requirement for medications, possible
hospitalisation, and adverse effects on nutritional status.33 A further exploration is required
into our documented association between peritonitis and death reported as Withdrawal. This
may be mislabelling by the Registry and a better understanding of the reasons for withdrawal
may provide additional insight into this association.
The strengths of this study include its large sample size and inclusiveness. We included all
patients in Australia during the study period that died whilst on PD, or within 30 days of
transferring to haemodialysis, this greatly enhanced the external validity of our findings. In
addition, the study methodology reduces the potential for confounding and accounts for the
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nature of the exposure. These strengths should be balanced against the study’s limitations, the
principal ones being that those patients sick enough to die may also be more likely to develop
peritonitis, and that we could not adjust for rapidly-changing patient factors. Our study does
not prove a causal link between peritonitis and mortality. In common with other Registries,
ANZDATA is a voluntary Registry and there is no external audit of data accuracy, including
the diagnosis of peritonitis and cause of death. Consequently, the possibility of
coding/classification bias cannot be excluded. It is also possible that physicians report
peritonitis events more often when they occur in close proximity to death. The study design
also will not correct for any potential time-varying confounders. As the data for this study is
obtained from a single region, and limited to those patients that had been on PD for a
minimum of 7 months, the results may not necessarily be generalizable to other PD
populations.

In conclusion, we have established for the first time that there is a significant association
between mortality and peritonitis. We recommend that a new definition of peritonitisassociated mortality be made that includes any death within 30 days following an episode of
peritonitis to reduce the chances of mislabelling.
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Concise methods:
All patients on the Australia and New Zealand Dialysis and Transplant (ANZDATA)
Registry that died on PD or within 30 days of transferring from PD to hemodialysis, between
1st May 2004 and 31st December 2009 were included in this study. Patients also had to be on
PD for a minimum of 7 months to allow a control period of time, distant to the time of death,
to compare the peritonitis rates with. Ethics approval was received from The University of
Western Australia.

The start date for peritonitis was defined as the date of diagnosis, based upon clinical features
of peritonitis (abdominal pain or cloudy dialysate) and dialysate leukocytosis (white blood
cell count > 100 /µL with > 50% neutrophils).34 Variables collected from the ANZDATA
Registry included dates of all diagnosis of peritonitis, patient demographic characteristics (ie.
age at time of death, gender, race, geographic remoteness at commencement of dialysis) and
clinical characteristics (ie. body mass index (BMI), cause of primary renal disease, comorbidities at the start of dialysis, smoking status, Kt/V, membrane transport characteristics
and cause of death). These data are collected by nursing and medical staff in each renal unit
in Australia and New Zealand and are submitted to the ANZDATA Registry annually.

Statistical analysis
We used a time-stratified case-crossover design whereby each patient acted as his or her own
control (Figure 4).11, 35 Two sampling periods were determined – i) the ‘case’ window,
immediately prior to the patient’s death, and ii) a ‘control’ window, of equal duration, distant
from the time of death. We varied the duration of these windows and the distance from the
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time of death in our analyses. Conditional logistic regression was used to compare the odds
of peritonitis in the 'case' window compared with the 'control' window for the same patient.
This method eliminated the influence of stable patient-level confounders, such as sex, race
and comorbidities. This method was used to assess the association between peritonitis and
all-cause mortality, death due to vascular disease (defined as death due to cardiovascular,
cerebrovacular or peripheral vascular disease), death due to infection and death due to
withdrawal of dialysis. Cause of death was defined by the treating physician.

Peritonitis may be more likely to occur the longer a patient is on dialysis, so a sensitivity
analysis was performed examining the relative risk of peritonitis in two 30 day windows that
are both distant from the time of death, including 6, 9 and 12 months. Another sensitivity
analysis was performed examining patients with one episode separately to patients with
multiple episodes of peritonitis.

Logistic regression was used to determine the patient demographic and clinical characteristics
predictive of peritonitis in the 30 days before death. Univariate models were initially used to
examine the relationship between each variable and peritonitis within 30-days of death. The
categorical variables examined were sex, age group (<60, 60-74, ≥75), state of residence,
Aboriginal or Torres Strait Islander status, BMI category (underweight <20, healthy 20-24.9,
overweight 25-29.9, obese ≥30), smoking status (current, former or never), membrane
transport status category (low <0.50, low average 0.50-0.64, high average 0.65-0.80, high
≥0.81), and comorbid diabetes, chronic lung disease, coronary heart disease, peripheral
vascular disease, and cerebrovascular disease (yes/no). The continuous variables examined
were time on PD (years) and number of peritonitis episodes. The linearity assumption was
tested by examining the interaction between these variables and their log transformations, and
14

was not violated in either case.36 Those variables significantly predicting peritonitis within 30
days of death (p <0.05) were included in a multivariate logistic regression model (coronary
heart disease, time on PD and number of peritonitis episodes).

Conditional logistic regression analyses were conducted in SAS version 9.2. All other
statistical procedures were conducted in IBM SPSS Statistics version 19.
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Figure 1: Days between peritonitis episode and death.
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Figure 2a: Odds of peritonitis in
different 5-day periods prior to
death compared with all other
preceding 5-day periods in the
year before death.

Figure 2b: Odds of peritonitis in
different 7-day periods prior to
death compared with all other
preceding 7-day periods in the
year before death.
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Figure 3 a. Odds of peritonitis in
different 30-day periods prior to
death from vascular disease
compared with all other
preceding 30-day periods in the
year before death. (n= 733)

Figure 3 b. Odds of peritonitis in
different 30-day periods prior to
death from Infection compared
with all other preceding 30-day
periods in the year before death.
(n=115 )

Figure 3 c. Odds of peritonitis in
different 30-day periods prior to
death from Withdrawal from
dialysis compared with all other
preceding 30-day periods in the
year before death. (n=174 )
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Figure 4. Case-crossover method in which individual patients serve as their own control. The
odds of peritonitis occurring within the case window (period immediately before death),
which can be of varying lengths, is compared to a control window (period remote from death,
in this figure 6 months prior) of equal duration.
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N

1316

Female

582 (44.2%)

Age at start of Peritoneal Dialysis (PD) (years)

67.5 (11.8) #

Age at death (years)

70.4 (11.7) #

Time on PD (years)

2.3 (1.4-3.9)*

State of residence:
New South Wales & Australian Capital
Territory

556 (42.2%)
234 (17.8%)

Victoria

125 (9.5%)

Western Australia

271 (20.6%)

Queensland

21 (1.6%)

Tasmania

88 (6.7%)

South Australia

21 (1.6%)

Northern Territory
Region of residence:
Major city

720 (54.7%)

Regional

345 (26.2%)

Remote

69 (5.3%)

Unknown

182 (13.8%)
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Ethnicity:
Caucasian

1023 (77.8%)

Asian

141 (10.7%)

Pacific

34 (2.6%)

Aboriginal and Torres Strait Islander

117 (8.9%)

Cause of death:
Peritonitis

78 (5.9%)

Other infection

115 (8.7%)

Cardiac

578 (43.9%)

Cerebrovascular

107 (8.1%)

Peripheral vascular

48 (3.6%)

Malignancy

96 (7.3%)

Withdrawal

174 (13.2%)

Other

120 (9.1%)

Number of peritonitis episodes:
None

584 (44.4%)

One

380 (28.9%)

Two

170 (12.9%)

Three or more

182 (13.8%)

Median days from peritonitis to death

247 (64-552)*
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Smoking status
Current

145 (11.0%)

Former

581 (44.1%)

Never

590 (44.8%)

Body Mass Index (kg/m2):
<20

106 (8.1%)

20.0-24.9

456 (34.9%)

25.0-29.9

472 (36.1%)

≥30

273 (20.9%)

Diabetes:
Type I

53 (4.0%)

Type II non-insulin requiring

330 (25.1%)

Type II insulin requiring

312 (23.7%)

Other comorbidities:
Chronic Lung Disease

369 (28.0%)

Coronary Artery Disease

1029 (78.2%)

Peripheral Vascular Disease

710 (54.4%)

Cerebrovascular Disease

508 (38.6%)

No comorbidity

78 (5.9%)
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Membrane transport status
Low

52 (4.0%)

Low average

327 (24.8%)

High average

479 (36.4%)

High

191 (14.5%)

Unknown

267 (20.3%)

Kt/V (total)

1.8 (0.6) #

Table 1: Cohort demographic and clinical characteristics.
#

mean (standard deviation)
*25th and 75th percentile
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Table 2: Odds ratio of peritonitis in the 30-days prior to death compared to the
30-day period 3, 6 and 9 months prior to death (with 95% confidence intervals).
Comparator month

Odds ratio

95% confidence intervals

3 months a

4.07

3.04-5.45

6 months a

6.23

4.44-8.74

9 months b

6.97

4.84-10.04

3 months c

8.36

4.80-14.55

6 months c

5.09

3.25-7.95

9 months d

11.10

5.81-21.20

All patients

Patients with 1 episode

a:n=1316
b:n=1221
c:n=380
d:n=359
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Table 3: Sensitivity analysis comparing the odds ratio of peritonitis in a 30-day window at two
different periods of time prior to death

Odds ratio

95% confidence intervals

6 months versus 9 months a

0.95

0.64-1.48

6 months versus 12 months b

0.81

0.51-1.27

6 months versus 9 months c

1.10

0.47-2.59

6 months versus 12 months d

0.91

0.39-2.14

All patients

Patients with 1 episode

a:n=1221
b:n=1120
c:n=359
d:n=328
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Table 4: Results from logistic regression showing odds of peritonitis in the 30-days prior to
death for selected patient demographic and clinical characteristicsa.
Odds ratio

95% confidence

P-value

intervals
History of coronary

0.71

0.51-0.99

0.048

1.07

1.00-1.15

0.049

1.71

1.55-1.89

<0.001

artery disease
Time on peritoneal
dialysis (years)b
Number of peritonitis
casesb
a: N = 1316.
b: Odds ratios refer to each unit increase.
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